The UK House of Commons’ Health and Social Care Committee has requested documents and evidence from Vertex Pharmaceuticals, NHS England and the National Institute for Health and Care Excellence (NICE) regarding ongoing and lengthy negotiations about NHS funding for the firm’s cystic fibrosis treatments.
Read More
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.
Read More
MPs are calling on NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.
Read More
Patients with cystic fibrosis will not get ‘routine’ access to treatment with Vertex’ Orkambi in England after the drug was ruled too expensive for NHS use.
Read More
